MA22878A1 - Combinaison synergique d'une substance a effet inhibiteur de la secretion d'acide gastrique et d'un antibiotique degradable en milieu acide. - Google Patents

Combinaison synergique d'une substance a effet inhibiteur de la secretion d'acide gastrique et d'un antibiotique degradable en milieu acide.

Info

Publication number
MA22878A1
MA22878A1 MA23171A MA23171A MA22878A1 MA 22878 A1 MA22878 A1 MA 22878A1 MA 23171 A MA23171 A MA 23171A MA 23171 A MA23171 A MA 23171A MA 22878 A1 MA22878 A1 MA 22878A1
Authority
MA
Morocco
Prior art keywords
substance
synergistic combination
secretion inhibitor
acid
degradable
Prior art date
Application number
MA23171A
Other languages
English (en)
Inventor
Sven Erik Sjostrand
Arne Torsten Eek
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26661401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA22878(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9201297A external-priority patent/SE9201297D0/xx
Priority claimed from SE9300029A external-priority patent/SE9300029D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of MA22878A1 publication Critical patent/MA22878A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06066—Needles, e.g. needle tip configurations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006—Properties of materials and coating materials
    • A61F2002/30092—Properties of materials and coating materials using shape memory or superelastic materials, e.g. nitinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A61F2210/0047—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply heated by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA23171A 1992-04-24 1993-04-21 Combinaison synergique d'une substance a effet inhibiteur de la secretion d'acide gastrique et d'un antibiotique degradable en milieu acide. MA22878A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201297A SE9201297D0 (sv) 1992-04-24 1992-04-24 Synergistic combination
SE9300029A SE9300029D0 (sv) 1993-01-08 1993-01-08 Synergistic combination ii

Publications (1)

Publication Number Publication Date
MA22878A1 true MA22878A1 (fr) 1993-12-31

Family

ID=26661401

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23171A MA22878A1 (fr) 1992-04-24 1993-04-21 Combinaison synergique d'une substance a effet inhibiteur de la secretion d'acide gastrique et d'un antibiotique degradable en milieu acide.

Country Status (38)

Country Link
US (3) US5599794A (fr)
EP (2) EP0956857A3 (fr)
JP (1) JPH07505901A (fr)
KR (1) KR100340165B1 (fr)
CN (1) CN1041798C (fr)
AP (1) AP466A (fr)
AT (1) ATE194286T1 (fr)
AU (1) AU669903B2 (fr)
CA (1) CA2133762C (fr)
CZ (1) CZ291201B6 (fr)
DE (2) DE637241T1 (fr)
DK (1) DK0637241T3 (fr)
DZ (1) DZ1683A1 (fr)
EE (1) EE03149B1 (fr)
ES (1) ES2100135T3 (fr)
FI (1) FI944953A7 (fr)
GR (2) GR970300011T1 (fr)
HR (1) HRP930755B1 (fr)
HU (1) HUT71225A (fr)
IL (1) IL105155A (fr)
IS (1) IS3990A (fr)
LV (1) LV12625B (fr)
MA (1) MA22878A1 (fr)
MY (1) MY121189A (fr)
NO (1) NO314288B1 (fr)
NZ (1) NZ252759A (fr)
PL (1) PL173485B1 (fr)
PT (1) PT637241E (fr)
RO (1) RO115780B1 (fr)
RU (1) RU2143899C1 (fr)
SG (1) SG52485A1 (fr)
SI (1) SI9300219B (fr)
SK (1) SK282420B6 (fr)
TN (1) TNSN93040A1 (fr)
TW (1) TW276996B (fr)
UA (1) UA43830C2 (fr)
WO (1) WO1993021920A1 (fr)
YU (1) YU49091B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CN1061232C (zh) * 1996-04-12 2001-01-31 马理国 一种治疗胃炎、溃疡的药物组合物
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
WO1999004816A1 (fr) * 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteur de la pompe a protons en combinaison therapeutique avec des substances antibacteriennes
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
CA2362930C (fr) * 1999-02-26 2010-10-05 Nitromed, Inc. Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
EP1313486A1 (fr) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Procedes de preparation de la clarithromycine et d'un intermediaire de la clarithromycine, notamment la clarithromycine exempte d'oxime, et composition pharmaceutique correspondante
CA2413923A1 (fr) * 2000-03-09 2001-09-13 Andrew Ilchyshyn Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal
EP1133987A1 (fr) * 2000-03-09 2001-09-19 Ian Whitcroft Traitement de dermatoses inflammatoires avec une combinaison d'erythromycine ou clarithromycine, métronidazole et un inhibiteur des pompes à hydrogène
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
SE0103695D0 (sv) 2001-11-07 2001-11-07 Thomas Boren A novel non-antibiotic strategy against OGIP infections based on a cereal product
WO2003063927A2 (fr) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions et procedes permettant de traiter les troubles gastro-intestinaux
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
JP4634144B2 (ja) * 2002-08-01 2011-02-16 ニコックス エスエー ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
JP2006516574A (ja) * 2003-02-05 2006-07-06 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール安定化方法
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06000524A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same
WO2007070164A1 (fr) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Composition pharmaceutique contenant un inhibiteur de la pompe a protons, un tampon et une substance active anti-h. pylori, et procedes d'utilisation associes
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008067037A2 (fr) 2006-10-05 2008-06-05 Santarus, Inc. Nouvelles formulations pour une libération immédiate d'inhibiteurs de pompe à protons et procédés d'utilisation de ces formulations
WO2008057802A2 (fr) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprenant des agents d'inhibition de la pompe à protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procédés d'utilisation
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10869690B2 (en) * 2017-06-29 2020-12-22 Ethicon Llc Trocar obturator with transverse needle ports
EP4598528A1 (fr) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition de calcification de valve aortique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
ES2066120T3 (es) * 1989-02-10 1995-03-01 Takeda Chemical Industries Ltd Uso de derivados de bencimidazol como agentes antibacterianos.
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
ES2169022T3 (es) * 1990-09-14 2002-07-01 Byk Gulden Lomberg Chem Fab Utilizacion de derivados de (piridil-metil-sulfinil)-1-h-bencimidazol para el tratamiento de enfermedades provocadas por helicobacter.

Also Published As

Publication number Publication date
MY121189A (en) 2006-01-28
SK282420B6 (sk) 2002-01-07
ATE194286T1 (de) 2000-07-15
HRP930755B1 (en) 2001-04-30
DK0637241T3 (da) 2000-09-11
IL105155A (en) 1999-05-09
US5599794A (en) 1997-02-04
NO314288B1 (no) 2003-03-03
AU669903B2 (en) 1996-06-27
YU49091B (sh) 2003-12-31
CA2133762C (fr) 2000-08-01
NZ252759A (en) 1996-12-20
TW276996B (fr) 1996-06-01
SI9300219A (sl) 1993-12-31
HRP930755A2 (en) 1994-10-31
YU27593A (sh) 1996-10-09
FI944953A0 (fi) 1994-10-21
AU4273793A (en) 1993-11-29
DE637241T1 (de) 1997-09-11
GR3034470T3 (en) 2000-12-29
EP0956857A3 (fr) 2003-11-26
US5629305A (en) 1997-05-13
EP0637241A1 (fr) 1995-02-08
CZ259394A3 (en) 1995-08-16
PT637241E (pt) 2000-10-31
IS3990A (is) 1993-10-25
EP0956857A2 (fr) 1999-11-17
SI9300219B (en) 2001-12-31
DE69328967T2 (de) 2000-12-07
DE69328967D1 (de) 2000-08-10
LV12625B (en) 2001-07-20
PL173485B1 (pl) 1998-03-31
ES2100135T3 (es) 2000-11-16
SK127594A3 (en) 1995-04-12
NO944010L (no) 1994-10-21
CN1081614A (zh) 1994-02-09
AP9300518A0 (en) 1993-04-30
CA2133762A1 (fr) 1993-11-11
FI944953L (fi) 1994-10-21
LV12625A (en) 2001-03-20
UA43830C2 (uk) 2002-01-15
EE03149B1 (et) 1999-02-15
NO944010D0 (no) 1994-10-21
EP0637241B1 (fr) 2000-07-05
ES2100135T1 (es) 1997-06-16
DZ1683A1 (fr) 2002-02-17
SG52485A1 (en) 1998-09-28
WO1993021920A1 (fr) 1993-11-11
HU9403069D0 (en) 1994-12-28
KR100340165B1 (ko) 2002-10-04
TNSN93040A1 (fr) 1994-03-17
RU2143899C1 (ru) 2000-01-10
FI944953A7 (fi) 1994-10-21
IL105155A0 (en) 1993-07-08
GR970300011T1 (en) 1997-05-31
HK1008296A1 (en) 1999-05-07
HUT71225A (en) 1995-11-28
JPH07505901A (ja) 1995-06-29
CN1041798C (zh) 1999-01-27
CZ291201B6 (cs) 2003-01-15
AP466A (en) 1996-03-05
US5633244A (en) 1997-05-27
RO115780B1 (ro) 2000-06-30

Similar Documents

Publication Publication Date Title
MA22878A1 (fr) Combinaison synergique d'une substance a effet inhibiteur de la secretion d'acide gastrique et d'un antibiotique degradable en milieu acide.
EP0690899A4 (fr) Fluides de forage biodegradable et non-toxiques
FI951965L (fi) Öljylisäaineet ja koostumukset
ID940B (id) Proses pemurnian asam karboksilat dan atau anhidridanya
CA2083390A1 (fr) Acide polyaspartique utilise comme inhibiteur du sulfate de calcium et du sulfate de baryum
FI922735A7 (fi) Uudet säiliöjärjestelmät ja vesipitoiset koostumukset
NO924978L (no) Chinolon- og naftyridon-karboksylsyrederivater
FI941747L (fi) Koostumuksia ja niiden käyttöjä
DE69411499D1 (de) Biologisch abbaubare Korrosionsinhibitoren mit niedriger Toxizität
NO922226D0 (no) 7-isoindolinyl-kinolon- og naftyridonkarboksylsyre-derivater
EP0821054A3 (fr) Utilisation d'acides polyaspartiques et de leurs sels
FI955851A7 (fi) Synergistisesti stabiloituja nestemäisiä entsymaattisia koostumuksia
BR9200058A (pt) Composto e composicao farmaceutica
FI956020L (fi) Pysyvä vesiformulaatio ja sen käyttö
ITMI910857A0 (it) Composizione acquosa gelificabile utile per modificare la permeabilita' in un giacimento petrolifero
FI944801A0 (fi) Öljypumppu ja sen kiristysletku
FI931000L (fi) Nedbrytbara polyamider
FR2677726B1 (fr) Differentiel a effet d'autoblocage.
FI934747A0 (fi) A-fosfonosulfonatskvalensyntetas-inhibitorer och foerfarande
DE69202892D1 (de) Föttinger Kupplung mit fester Flüssigkeitsmenge und Haupt- und Hilfsverzögerungskammer.
FI931039A7 (fi) Parannettuja voiteluainekoostumuksia ja niissä käyttökelpoisia lisäain eita
PL308201A1 (en) Applicationj of hialuronic acid and various forms thereof in preventing recurrent arteriostenosis
NO943373D0 (no) Psyliumholdig sammensatt blandingsdrikk
ES2094437T3 (es) Poliamida termoplastica de reducida inflamabilidad.
FR2714292B1 (fr) Association d'acétylsalicylate de DL-lysine et de vitamine E.